Abstract 4124
Background
Lung cancer is one of the most fatal cancer types globally. Currently, the immune status in the tumor microenvironment (TME) is highly valued. The immune status includes the expression of checkpoint molecules, co-stimulatory molecules, tumor-infiltrated lymphocyte status and TCR signal status, etc., which harbor different mechanisms in regulating the immune cells in the TME. However, the expression status of some biomarkers may have inner statistical characteristics, which may leave clues to the immune status and related clinical outcomes. In this study, a panel of 9 immune biomarkers was selected for the possible prediction of clinical outcomes in early stage resectable NSCLC.
Methods
Immunohistochemistry (IHC) was performed on surgical samples from 139 patients with NSCLC. Cox regression analysis and subgroup analysis of OS and RFS were conducted for the screening of biomarkers. The Principle Component Analysis (PCA) was conducted on screened biomarkers, including factorial analysis, principle component regression and principle component ranking. A database search was performed in order to verify the clinical characteristics. An Artificial Neuron Network analysis was established for the prediction of clinical outcomes.
Results
6 out of 9 biomarkers are considered significant and were selected for the data analysis. The KMO-Bartlett’s Sphericity test is valid (0.658>0.5, p = 0.0001). The principle component regression results indicate the OS is correlated with the principle component Z4(Y = 0.316×Z4 + 2.298, R = 0.189, p = 0.026). Also, the PFS also correlated with the principle component Z4 and Z2 (Y = 0.314×Z4 + 0.255×Z2 + 2.061, R = 0.249, p = 0.013). Principle components ranking (PCrank) is calculated and after the determination of cutoff 0.2, the intergroup comparison of subgrouphigh and subgrouplow is significant in OS (p = 0.025). Database searching validates our results. The ANN model successfully predicts the clinical outcome, with the testing accuracy of 94.1% and 96.2% in models 1 and 2, respectively.
Conclusions
The selected immunological panel has promising potential in predicting the prognosis of resectable NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported in part by a grant from National Natural Science Foundation of China (81802255), Shanghai Pujiang Program (17PJD036) and a grant from Shanghai Municipal Commission of Health and Family Planning Program (20174Y0131). National key research & development project (2016YFC0902300). Major disease clinical skills enhancement program of three year action plan for promoting clinical skills and clinical innovation in municipal hospitals, Shanghai Shen Kang Hospital Development Center Clinical Research Plan of SHDC (16CR1001A). The fundamental research funds for the central universities.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3158 - Tobacco Retail Access and Tobacco Cessation Among Head and Neck Cancer (HNC) Survivors
Presenter: Lawson Eng
Session: Poster Display session 1
Resources:
Abstract
5511 - ASSERT: A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Patients Treated for Moderate to Severe Hyponatremia Secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) in Italy (Lung Cancer Cohort)
Presenter: Rossana Berardi
Session: Poster Display session 1
Resources:
Abstract
3821 - Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: A systematic review and meta-analysis.
Presenter: Benedetta Bonardi
Session: Poster Display session 1
Resources:
Abstract
2168 - Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
Presenter: Tineke Vandenbroucke
Session: Poster Display session 1
Resources:
Abstract
5855 - Update of the registry of young women with cancer by the International Network of Cancer, Infertility and Pregnancy
Presenter: Charlotte Maggen
Session: Poster Display session 1
Resources:
Abstract
5156 - Erectile dysfunction in patients with metastatic renal cell carcinoma
Presenter: Ilya Tsimafeyeu
Session: Poster Display session 1
Resources:
Abstract
4992 - Exercise level, interest and preferences in cancer patients.
Presenter: Alice Avancini
Session: Poster Display session 1
Resources:
Abstract
3427 - Filling the Gaps in Informed Consent for Advanced Cancer Patients considering Phase 1 Oncology Trials - an in-depth Qualitative Study of Key Stakeholders at a large United Kingdom Phase 1 unit
Presenter: Abhijit Pal
Session: Poster Display session 1
Resources:
Abstract
3537 - Breast Cancer Patients’ Quality of Life: Real World Data
Presenter: Thanos Kosmidis
Session: Poster Display session 1
Resources:
Abstract
4761 - High-sensitivity troponin as a cardiotoxicity biomarker in breast cancer treatment
Presenter: Joana Simões
Session: Poster Display session 1
Resources:
Abstract